IL1B and cancer: Thus, agents that inhibited the IL-1/IL-1β included IL-1Ra (anakinra), IL-1β antibody (canakinumab), and the inflammasome inhibitor (MCC950) have potential anti-tumor activity in cancers [121, 122].